INTRODUCTION

Leukotrienes (LTs) are a family of inflammatory mediators derived from arachidonic acid.\(^1\) 5-Lipoxygenase (5-LO) is the key enzyme in LT biosynthesis as it catalyzes the two-step oxygenation of arachidonic acid forming LTA\(_4\).\(^2,3\) LTA\(_4\) can then be hydrolyzed to LTB\(_4\) by a reaction catalyzed by LTA\(_4\) hydrolase or to the cysteinyl leukotrienes by LTC\(_4\) synthase.\(^4-6\) LTB\(_4\) is a potent leukocyte chemoattractant and cell activator. LTB\(_4\) and cysteinyl-LT are implicated in vascular permeability and bronchoconstriction.\(^7\)
Although inflammation is a defense mechanism vital to health, it also contributes to the development and progression of many chronic diseases.\(^5\)\(^-\)\(^11\) 5-LO and leukotrienes are intimately involved in the progression of inflammatory diseases like asthma, atherosclerosis and rheumatoid arthritis.\(^12\)\(^-\)\(^15\) Several key proteins associated with LT biosynthesis and action, including 5-LO, have been investigated and validated as antiinflammatory targets.\(^16\) To date, zileuton (1) (Zyflo\(^\text{®}\)) (Figure 1) is the only drug which targets the leukotriene pathway through the inhibition of 5-LO and is clinically approved in the United States for the chronic treatment of asthma.\(^17\) However, its use is limited due to hepatic side effects and an unfavorable pharmacokinetic profile.\(^18\)\(^-\)\(^20\) Hence the pursuit of new compounds targeting 5-LO and the LT pathway remains an active area of research and clinical development.\(^21\)

Several natural compounds have been investigated as potential 5-LO inhibitors. Among these is caffeic acid phenethyl ester (CAPE) (2) (Figure 1), a bioactive component of honeybee propolis\(^22\) that has been reported to have beneficial health properties, including antiinflammatory activity.\(^23\)\(^-\)\(^26\) Of importance, CAPE (2) inhibits LT biosynthesis in isolated human neutrophils with an IC\(_{50}\) (0.5 µmol/L) that is lower than that of zileuton (1) and that is similar (1.8 µmol/L) to that of zileuton (1) in whole blood.\(^27\)\(^,\)\(^28\) This suggests that while remaining a potent inhibitor of LT biosynthesis, the susceptibility of CAPE (2) to modifications such as hydrolysis by esterases may reduce its potency in a physiological setting since caffeic acid itself is a poor 5-LO inhibitor.\(^27\)

Several analogues of CAPE (2) have been developed based on modifications of the caffeic moiety or of the ester linkage, and some have shown improved inhibition of leukotriene biosynthesis.\(^27\)\(^,\)\(^29\)\(^,\)\(^30\) In this study, CAPE (2) analogues in which the catechol moiety was modified and/or the ester bond was replaced with a ketone were investigated for their impact on the inhibition of leukotriene biosynthesis in human neutrophils and whole blood. Additionally, the stability of the compounds was evaluated in whole blood and in the human hepatocyte HepaRG cell model, and metabolites were identified using liquid chromatography-mass spectrometry (LC-MS/MS). In summary, sinapic acid and 2,5-dihydroxy derivatives displayed a better inhibitory activity than caffeic acid derivatives and the ketone analogues displayed superior inhibition and stability. All compounds were modified by glucuronidation, however, the glucuronidated sinapic acid ketone analogue retained significant inhibitory activity.

## METHODS

### 2.1 Synthesis of CAPE-like analogues

Ester and ketone analogues of CAPE (2) were synthesized by one pot esterification or an aldol condensation, respectively, as previously reported.\(^29\)\(^,\)\(^30\)

\[\text{Zileuton (1)} \quad \text{CAPE (2)}\]

**FIGURE 1** Structures of Zileuton (1) and CAPE (2)

### 2.2 Cell culture

HEK293 cells were obtained from ATCC (Manassas) and were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum. Cells were stably transfected with 5-lipoxygenase and 5-lipoxygenase activating protein (FLAP) as previously described.\(^31\)

Undifferentiated cryopreserved HepaRG cells (BioPredic International) were seeded in 12 or 24 well plates at 1.1 × 10\(^5\) and 0.55 × 10\(^5\) cells per well, respectively. Cells were cultured for 14 days in Williams E-medium supplemented with 1% penicillin-streptomycin (10 000 U/mL), 10% fetal bovine serum (FBS), 50 mg/L hydrocortisone hemisuccinate, 5 mg/L insulin and 2 mmol/L Glutamax, and the medium was renewed every 2-3 days. After 14 days, the culture medium was replaced by the same formulation as above supplemented with 2% dimethyl sulfoxide (DMSO) to induce differentiation. Cells were considered differentiated and ready for experiments after 14 days of differentiation (28 days after seeding).

### 2.3 HEK293 cell stimulation and measurement of 5-LO products

Transfected HEK293 cells were collected and resuspended in Hank’s balanced salt solution (HBSS, Lonza) containing 1.6 mmol/L CaCl\(_2\) at a concentration of 5 × 10\(^5\) cells/mL, and were preincubated with each compound at concentration of 1 µmol/L for 5 minutes at 37°C.

Cells were then stimulated for 15 minutes at 37°C with the addition of 10 µmol/L calcium ionophore A23187 (Sigma-Aldrich) and 10 µmol/L arachidonic acid (Cayman Chemical).\(^28\) Stimulations were stopped by adding 0.5 volume of cold CH\(_3\)OH:CH\(_3\)CN (1:1) containing 100 ng/mL of prostaglandin B\(_2\) (PGB\(_2\)) as internal standard. Samples were stored at −20°C and analyzed for 5-LO products using reversed-phase high-performance liquid chromatography (RP-HPLC) as described previously.\(^32\)

### 2.4 Isolation and stimulation of polymorphonuclear leukocytes

Heparinized blood (see Ethics statement) was collected, centrifuged at 200g for 10 minutes to collect plasma, and erythrocytes were sedimented in dextran. PMNL were obtained after centrifugation on a lymphocyte separation medium cushion (density, 1.077 g/mL) (Wisent) at 900 g for 20 minutes, followed by hypotonic lysis to remove residual erythrocytes.\(^33\) PMNL were counted and resuspended at 10\(^7\) cells/mL in HBSS supplemented with 1.6 mmol/L CaCl\(_2\) and 0.3 U/mL adenosine deaminase (Sigma-Aldrich). PMNL were preincubated with the test compounds or their diluent (0.1% DMSO) for 5 minutes at 37°C and were then stimulated with 1 µmol/L thapsigargin (Sigma-Aldrich) for 15 minutes at 37°C.\(^27\) Reactions were stopped by adding two volumes of CH\(_3\)OH:CH\(_3\)CN (1:1) containing the internal standard PGB\(_2\) (100 ng/mL), and samples were processed for RP-HPLC analysis of 5-LO products.
In some experiments, platelets were removed from plasma by centrifugation at 2000g for 20 minutes, and test compounds were incubated in plasma for up to 60 minutes prior to addition to PMNL suspensions for subsequent stimulation and detection of 5-LO products as described above.

2.5 | Ex vivo whole blood stimulation

Blood was collected in tubes containing heparin as anticoagulant. Test compounds or their diluent control (DMSO, 0.1%) were added to 1 mL of heparinized blood at the indicated concentrations and incubated for 5 minutes in a water bath at 37°C. Stimulation was initiated with the addition of 125 µL of 40 mg/mL of opsonized zymosan, samples were then gently vortexed and incubated at 37°C for 30 minutes.34 Samples were then centrifuged at 960g for 10 minutes at 4°C, plasma was removed and added to tubes containing 4 volumes of CH₃OH:CH₂CN (1:1) containing 100 ng/mL of PGB₂, as internal standard. Samples were stored overnight at −20°C, and then centrifuged at 3300g for 10 minutes. Samples were then purified on C18 cartridges, eluted with CH₃OH, dried under nitrogen, resuspended in 46% of CH₃OH:CH₂CN (1:1), and analyzed using RP-HPLC as described above.

In some experiments, test compounds were incubated in blood for up to 120 minutes prior to stimulation with opsonized zymosan and detection of 5-LO products as described above.

2.6 | Incubation of test compounds with HepaRG cells

Differentiated HepaRG cells, plated in 24 well plates, were washed with hepatocyte suspension medium (Williams E-medium without phenol red, supplemented with 2 mmol/L Glutamax and 12.5 mL HEPEs) before addition of hepatocyte suspension medium (250 µL/well) containing (30 or 50 µmol/L) of the test compounds or their diluent. Cells were then incubated for 7.5, 15, 30, 60 or 90 minutes at 37°C after which the medium was removed.

In experiments where the test compounds incubated with HepaRG cells were to be measured, the cell layer was washed with 250 µL of hepatocyte suspension medium which was then pooled with the first medium. The mixture was then added to 250 µL of ice cold CH₃OH:CH₂CN (1:1, vol:vol) containing 10 µmol/L of phenethyl 3,4,5-trimethoxycinnamate as an internal standard. The resulting solution was frozen at −80°C for 2 hour to precipitate any dissolved proteins, centrifuged at 1800g and the supernatant transferred to vials and stored at −20°C until HPLC analysis. Samples were then preconcentrated by in-line solid phase extraction (Waters Oasis HLB 3.9 × 20 mm 15 µm Particle Size) followed by reverse phase HPLC (EMD Millipore Chromolith® HighResolution RP-18 endcapped 100 × 4.6 mm) on a linear gradient of 10% CH₂CN in H₂O + 0.1% formic acid to 100% CH₂CN + 0.1% formic acid over 10 minutes at 2.2 mL/min with detection using a diode array at 270 nm (compounds 5, 8, Zileuton (1)) and 328 nm (CAPE (2), 7, 9, 10) for detection and relative quantitation of test compounds.

In experiments where the inhibitory capacity of test compounds was to be determined after incubation with HepaRG cells, 125 µL of the hepatocyte suspension medium containing test compounds that had been collected at different time points from HepaRG cultures was added to 1 mL of heparinized blood. After a 5 minutes of preincubation, blood was then stimulated with opsonized zymosan and processed for HPLC analysis of 5-LO metabolites as described above.

In other experiments, LC-MS/MS analysis was performed to identify metabolites of test compounds that had been incubated with HepaRG cells. First, fifty micromolar standards of the test compounds were diluted 3000-fold and analyzed using electro-spray ionization mass spectrometry on a linear quadrupole ion trap (LTQ-XL) from Thermo-Fisher Scientific (San Jose). Full scan spectra were collected using both ionization polarities for confirmation of the intact molecular weight of each compounds based on the expected [M + H]⁺ and [M−H]⁻ pseudo-molecular ions observed using mass spectrometry. The diluted standards were then subjected to reversed-phase partition chromatography on an Altima C18 column produced by HiChrom and distributed by VWR (Mississauga, ON). The LC system was a Dionex Ultimate 3000. The mass spectrometer electrospray source was used at 40 µL/min with a nitrogen sheath gas of 15, a spray voltage of ±4 kV, a capillary voltage of ±35 V, a tube lens of ±175 V and a capillary temperature of 160°C. Samples that had been collected from HepaRG cultures were purified on C18 cartridges and eluted with CH₂OH. For the first injection of extracted samples, the MS method consisted of a repeated loop of full scan (m/z 100-800), product ion scan based on the intact mass determined from infusion of the standards and one product ion scan. Subsequent injection of all samples from both time points were performed with individualized scanning functions for each treatment in negative ion mode only. The scan functions consisted of a cycle of full scan (ie, m/z −100 to −800), a product ion scan of the input compound as well as a product ion scan of the identified metabolite.

2.7 | Docking

Docking of all inhibitors into the active site of the crystal structures of human 5-LO (PDB code: 3O8Y, 2.39 Å resolution)35 as well as the calculations of the affinities of the test molecules was performed with the AutoDock vina.36

2.8 | Statistics

Statistical analysis and graph design were performed with GraphPad Prism 6 software (GraphPad Software). IC₅₀ values were calculated from a sigmoidal concentration-response curve-fitting model. Half-life time values were calculated from exponential decay curves. IC₅₀ and half lifetime values are expressed as means with 95% confidence intervals. One-way ANOVA or two-way
ANOVA with Dunnett’s multiple comparison test was performed to determine significant difference from controls \((P < .05)\). Data are expressed as means ± SEM.

3 | RESULTS

3.1 | Biosynthesis of 5-LO products

Elimination of the catechol or modifications of the functional groups on the caffeic moiety of CAPE has resulted in compounds that poorly inhibit LT biosynthesis,\(^27\,29\) with the exception of the sinapic acid (2,4-dimethoxy, 3-hydroxy) derivative that results in better inhibitory activity than CAPE \((\text{2})\).\(^29\) Therefore, a first series of experiments used a HEK293 cell model that ectopically expresses 5-LO and FLAP to screen other dihydroxy isomers of CAPE to determine if the positions of the hydroxyl groups are of importance. The HEK293 cells were incubated with 1 \(\mu\)mol/L of CAPE \((\text{2})\) or its dihydroxy isomers \(3, 4, 5,\) and \(6\) (Figure 2A) prior to stimulation. Figure 2B shows that the positive control, zileuton \((\text{1})\), was less effective than CAPE \((\text{2})\), but that compounds \(3\) and \(5\) exhibited very good inhibitory activity similar to that of CAPE \((\text{2})\), whereas compounds \(4\) and \(6\) were without measurable effect. Therefore, the position of the two hydroxyl groups is of importance for 5-LO inhibition.

After screening in the HEK293 cell model, in a second set of experiments the inhibitory activity on LT biosynthesis of the three compounds showing the best inhibitory activity, CAPE \((\text{2})\) and \(5\), as well as sinapic acid phenethylester \((\text{9})\),\(^29\) was compared in stimulated human PMNL. Since ketone derivatives of CAPE \((\text{2})\) and compound \(5\) \((\text{5, 6, 7, and 8})\) were previously shown to also exhibit significant inhibition,\(^30\,37\) a ketone derivative of \(9\) (compound

![Figure 2](image1.png)

**Figure 2** The structures of the tested compounds (A) and their effects on the biosynthesis of 5-LO products in transfected HEK293 cells (B). HEK293 cells expressing 5-LO and FLAP were incubated in presence of the indicated compounds (1 \(\mu\)mol/L) or their diluent (Control, 0.1% DMSO) for 5 minutes, followed by the addition of 10 \(\mu\)mol/L calcium ionophore A23187 and 10 \(\mu\)mol/L arachidonic acid for 15 minutes. Reactions were then stopped, and samples were processed for analysis of 5-LO products using RP-HPLC. Total 5-LO products measured represent the sum of LTB\(_4\), its trans isomers and 5-hydroxyeicosatetraenoic acid. Data are expressed as means ± SEM of at least three independent experiments. *Difference from control as determined using one-way ANOVA with Dunnett’s multiple comparison test \((P < .05)\)

![Figure 3](image2.png)

**Figure 3** The structure of the test compounds and their effect on the biosynthesis of 5-LO products in PMNL. (A) The structures of CAPE \((\text{2})\) and its analogues investigated in this study. (B) Isolated human PMNL were incubated in presence of test compounds (1 \(\mu\)mol/L) or their diluent (Control, 0.1% DMSO) for 5 minutes. PMNL were stimulated with 1 \(\mu\)mol/L of thapsigargin for 15 minutes at 37°C. The stimulation was then stopped, and samples were processed for analysis of 5-LO products using RP-HPLC. Total 5-LO products measured represent LTB\(_4\), its trans isomers, 20-OH-LTB\(_4\), 20-COOH-LTB\(_4\) and 5-hydroxyeicosatetraenoic acid. Data are expressed as means ± SEM of at least three independent experiments. *Difference from control, as determined using one-way ANOVA with Dunnett’s multiple comparison test \((P < .05)\)
(Figure 3A) was also synthesized and tested for inhibitory activity. All six test compounds showed a significant inhibition of LT biosynthesis in human PMNL, with compounds 5, 7 and 10 showing a near complete inhibition at the tested concentration (Figure 3B).

Since all six selected test compounds showed significant inhibition at a concentration of 1 µmol/L, the compounds were screened further in concentration-response studies to better characterize their relative inhibitory capacities in stimulated PMNL and in whole blood (Table 1). All compounds were assayed at concentrations of 0, 0.1, 0.3, 1 and 3 µmol/L in PMNL and 0, 0.1, 0.3, 1, 3 and 10 µmol/L in whole blood in order to obtain dose-response curves, from which IC50 values were calculated.

In PMNL, all compounds outperformed CAPE (2) and possessed IC50 values that were significantly lower than the clinically approved 5-LO inhibitor Zileuton (1). However, in whole blood, although Zileuton (1) had a lower IC50 value than CAPE (2), compounds 7 and 9 were similar to zileuton, while compounds 5, 8 and 10 all showed lower IC50 values than zileuton.

### 3.2 | Molecular docking

Docking of all inhibitors into the active site of the crystal structures of human 5-LO (PDB code: 3O8Y, 2.39 Å resolution)35 was performed with AutoDock Vina. As shown in Table 2, all compounds showed affinity for the active site, with compound 8 scoring the best affinity with a docking energy of −9.1 kcal/mol. A hydrogen bond with His 600 (OH···N: 3.22 Å) was detected by LigPlot+. Compound 8 also had π-π interactions with His 367 and His 372, both of which coordinate the iron atom35 while His372 may act as a replaceable coordinating ligand for the iron atom.38 Compound 5 (−8.8 kcal/mol) had interactions that were very similar to compound 8 forming a hydrogen bond with His 600 (OH···N: 3.22 Å) and a π-π interaction with His 372.

The remaining ligands had a similar affinity energy, with the exception of Zileuton (1) that showed lower affinity for both active enantiomers. CAPE (2) (−8.8 kcal/mol) formed a hydrogen bond with Leu 420 (OH···O: 3.07 Å) and a π-π interaction with His 372.

### TABLE 1 | Calculated IC50 values of selected compounds for the inhibition of 5-LO product biosynthesis in human PMNL and in whole blood

| Compounds | PMNL IC50 (µmol/L) | Whole blood IC50 (µmol/L) |
|-----------|---------------------|---------------------------|
| Zileuton (1) | 2.30 (1.95-2.72) | 1.93 (1.57-2.37) |
| CAPE (2) | 0.97 (0.85-1.10) | 3.58 (3.03-4.24) |
| 7 | 0.52 (0.45-0.61) | 2.30 (1.72-3.08) |
| 5 | 0.32 (0.29-0.36) | 1.00 (0.88-1.14) |
| 8 | 0.51 (0.44-0.58) | 1.15 (0.99-1.34) |
| 9 | 0.29 (0.27-0.32) | 1.91 (1.51-2.41) |
| 10 | 0.41 (0.36-0.46) | 1.20 (0.98-1.46) |

Note: Values are means (95% confidence interval) from at least three independent experiments.

Compound 7 (−8.9 kcal/mol) underwent pi-pi interactions with His367 and was the only tested ligand that showed a π-π interaction with Phe177 which may play a part in product specificity.39 Compounds 9 (−8.7 kcal/mol) and 10 (−8.7 kcal/mol) had pi-pi interactions with His 372. Overall, all molecules showed affinity for the active site although the calculated affinities do not appear to correlate with IC50 data.

All tested ligands had the same orientation (data not shown) with the substituted benzene portion of the molecules pointing towards the end of the cavity and the nonsubstituted portion approaching the iron atom. The ligands had a slightly different pose from each other. Compounds 9 and 10 were partially superimposed on the substituted ring but they differed after the double bond in the connecting chain due the greater flexibility allowed by the missing ester group which is substituted by a carbonyl group in compound 10.

### 3.3 | In silico physicochemical properties and drug-likeness evaluation

The physicochemical properties of the selected compounds were evaluated to determine if they are within the Lipinski's Rule of Five, which is important for pharmacokinetics and drug development.

For this purpose, physicochemical and ADME (absorption, distribution, metabolism, and excretion) properties were calculated using the SwissADME (a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules) (Table 3). Compounds obeying at least three of the four criteria are considered to adhere to Lipinski Rule,40 and all tested compounds were compatible with Lipinski Rule. Other properties of interest are the number of rotatable bonds and the topological polar surface area (TPSA). Compounds with many rotatable bonds (>10) have been associated with poor oral bioavailability41 while compounds with a low TPSA (<140 Å2) tend to have higher oral bioavailability.41,42 All tested compounds showed favorable PSA and number of rotatable bonds.

### 3.4 | Stability of test compounds in plasma and whole blood

The stability of the inhibitory activity of the test compounds was evaluated in human plasma and in whole blood. Firstly, compounds were incubated at 37°C for various times in human plasma and were then evaluated for their ability to inhibit the stimulated biosynthesis of 5-LO products in human PMNL. Figure 4A shows that all compounds had a steady inhibitory effect over time which suggests that the compounds are stable in plasma. A second series of experiments was performed in whole blood by incubating the test compounds or their diluent (DMSO 0.1%) for various times in whole blood prior to stimulation with zymosan. Unlike human plasma results, the inhibitory effect of CAPE (2) and compound 7, the two compounds with catechol groups, decreased over time with a complete loss of inhibitory activity after 240 minutes of incubation (Figure 4B). The inhibitory activity of all other compounds remained quite stable over
time, with only compound 8 showing approximately 25%-35% loss of activity after 2-4 hours of incubation in blood.

### 3.5 Stability of test compounds in HepaRG cell culture

HepaRG cells can be differentiated into hepatocytes and biliary-like epithelial cells and maintain liver functions such as expression of drug metabolizing enzymes and transporters. Therefore, this is a valuable in vitro model to assess the potential hepatic stability of experimental compounds. To study the kinetics of test compound stability and its effects on the biosynthesis of LTB₄, the test compounds were incubated with HepaRG cells and the culture medium was then collected at different times to measure their remaining presence and the residual capacity to inhibit the biosynthesis of 5-LO products.

Based on the relative peak area for each compound compared to unmetabolized starting material (t = 0) following separation by HPLC, peaks associated with all three ester-linked compounds 2, 5 and 9 disappeared from HPLC chromatograms more quickly (Figure 5A) and exhibited shorter half-lives (Figure 5B) than their ketone counterparts. The sinapic acid ketone analogue 10 had a significantly greater half-life than all other analogues.

The loss of inhibitory activity of the test compounds (Figure 6) followed a similar pattern to that of their disappearance from the cell culture medium. After 15 minutes most compounds lost some inhibitory activity against 5-LO product biosynthesis, although the loss of biological activity was not as apparent as the loss of peak height seen in Figure 5. After 60 minutes CAPE (2), compounds 7, 5, 8 and 9 had lost all their inhibitory activity (Figure 6). However, compound 10 lost its inhibitory activity much more slowly over time and maintained significant inhibition of the biosynthesis of 5-LO products after 60 minutes despite its complete disappearance from culture medium as shown in Figure 5. The comparator compound zileuton inhibited the 5-LO product biosynthesis in a steady manner over time.

### 3.6 Identification of metabolites following incubation of test compounds in HepaRG cell culture

The goal of the next set of experiments was to identify using LC-MS/MS the metabolites formed following incubation with HepaRG cells.
Firstly, the retention time and fragmentation pattern were determined using negative ion and positive ion LC-MS/MS for each test compound prior to incubation with cells. Table S1 shows that the expected mass for each compound was obtained using LC-MS and also shows the mass of the fragments obtained and the HPLC retention times. HepaRG cells were then incubated in the presence of each test compound for 7.5 and 60 minutes at 37°C and the supernatants were analyzed using LC-MS/MS.
with Dunnett’s multiple comparison test (*Difference from time = 0, as determined using One‐way ANOVA of CH3OH:CH3CN (1:1). Samples were processed for analysis using RP‐HPLC for LTB4 quantification. Data are expressed as means ± SEM of at least three independent experiments. *Difference from time = 0, as determined using One‐way ANOVA with Dunnett’s multiple comparison test (P < .05)

**FIGURE 6** Stability of the test compounds for the inhibition of the biosynthesis of 5‐LO products following incubation with HepaRG cells. HepaRG cells were incubated with 500 µL of hepatocyte suspension medium containing 50 µmol/L of test compounds for the indicated times at 37°C. Hepatocyte suspension medium (125 µL) was then removed and added to 1 mL of blood that was then incubated for 5 minutes and then stimulated with opsonized zymosan (4 mg/mL) for 30 minutes at 37°C. Blood was then centrifuged and plasma was collected and added to 1.2 mL of CH3OH:CH3CN (1:1). Samples were processed for analysis using RP‐HPLC for LTB4 quantification. Data are expressed as means ± SEM of at least three independent experiments. *Difference from time = 0, as determined using One‐way ANOVA with Dunnett’s multiple comparison test (P < .05)

Figure 7A shows the negative ion LC‐MS analysis of CAPE (2) following incubation with HepaRG cells for 7.5 and 60 minutes. At 7.5 minutes, the total ion chromatogram (TIC) shows one peak that corresponds to the retention time and mass of CAPE (m/z‐283), however after 60 minutes a second peak appears with m/z‐459. Single ion monitoring (SIM) of the second peak shows that the compound with m/z‐459 was also present at 7.5 minutes. The fragmentation of this second peak by MS/MS shows a fragment with a mass of [M‐H‐176] that corresponds to the expected mass of glucuronic acid. A similar profile was also seen for the keto analogue of CAPE (2), compound 7 (Figure 7B). The results of the mass spectral analyses of all test compounds are summarized in Table S1B.

Additionally, the presence of [M + H2H2]+ ions seen in Figure 7B suggests the hydrogenation of a double bond. In fact, this pattern was observed for all keto compounds 7, 8 and 10 that had been incubated with HepaRG cells but not for their respective esters. The SIM chromatograms obtained with the respective metabolite’s mass and that of the M + H2 ions show that the peaks are resolved for compounds 8 and 10, but not 7 (Figure 7C). This suggests that these compounds undergo α,β-unsaturated ketone reduction in these culture conditions. Based on the relative peak areas, a significant proportion of the molecules undergo hydrogenation.

**4 | DISCUSSION**

5‐Lipoxygenase and its products, the leukotrienes, are intimately involved in the inflammatory response and have been targeted for the treatment of asthma for over two decades with the development of the 5‐LO inhibitor zileuton (Zyflo®) and the cys‐leukotriene‐1 (Cys‐LT1) receptor antagonists montelukast (Singulair®) and zafirlukast (Accolate®). More recently, 5‐LO has been identified as a potential therapeutic target for conditions such as rheumatoid arthritis,45,46 atherosclerosis,47‐49 Alzheimer’s disease50 and leukemia stem cells.51,52 However, zileuton has poor pharmacokinetic properties and liver toxicity issues, whereas the Cys‐LT1 receptor antagonists only target the cys‐LTs and not the LTB4 receptors that play an important role in several pathologies. Therefore, there is interest for the development of effective 5‐LO inhibitors.21

In this study, analogues of the natural polyphenolic compound CAPE (2) were synthesized and evaluated as 5‐LO inhibitors. CAPE is a potent 5‐LO inhibitor with IC50 values in the high nmol/L to low µmol/L range in isolated human neutrophils and in whole human blood, respectively.27 However, its stability as a drug candidate has been questioned partly because of its susceptibility to esterases53 that catalyze its hydrolysis to the much less active caffeic acid.27 The analogues described in this study include ketones that are not susceptible to esterase action, as well as analogues of the caffeoyl moiety of the molecule that show enhanced inhibitory activity toward the biosynthesis of 5‐LO products. Some of these analogues were shown to be more resistant to degradation and to loss of inhibitory activity following incubation in HepaRG cell culture and in whole human blood.

With regard to the caffeoyl moiety of CAPE (2), it was previously shown that cinnamic acid phenethyl ester, devoid of the vicinal hydroxyl groups, and various monohydroxy derivatives of CAPE (2) do not inhibit LT biosynthesis at concentrations up to 10 µmol/L.27,29 Similarly, mono, di‐ and tri‐methoxy derivatives of CAPE (2) are also without inhibitory activity.29 The only other substitution previously tested that results in inhibitory activity similar to or better than CAPE (2) was the sinapic acid (3,5‐dimethoxy, 4‐hydroxy) derivative, compound 9.29 This study provides additional information regarding the impact of substitutions on the caffeoyl moiety. Unlike CAPE (2), the 2,4‐dihydroxy and the 3,5‐dihydroxy compounds 4 and 6, respectively, were without inhibitory activity at the tested concentrations, whereas the 2,5‐dihydroxy compound 5 showed superior inhibition of 5‐LO product biosynthesis compared to CAPE (2) in isolated PMNL and in whole blood. In fact, compound 5 was equivalent to the sinapic acid derivative 9 in isolated PMNL and showed superior inhibition in whole blood. Therefore, the position of the hydroxyl groups on the phenol is critical to the capacity to inhibit 5‐LO product biosynthesis.
Although CAPE (2) and compounds 5 and 9 exhibited important inhibitory activity in short-term incubations in isolated PMNL and whole blood, previous studies showed that CAPE (2) is rapidly hydrolyzed to caffeic acid in rat plasma (but not in human plasma) by a carboxylesterase, and oral administration to rats also results in excretion of caffeic acid as the major metabolite in the urine.53–55 Since an effective drug candidate should not be enzymatically labile in plasma, CAPE analogues were synthesized with structural modifications of the ester bond. It was previously shown that an amide analogue of CAPE inhibited LT biosynthesis and 5-LO activity, though with reduced potency compared to CAPE.27 However, ketone derivatives of CAPE (2) have shown inhibition of 5-LO product biosynthesis in human PMNL that appear to be superior to that of CAPE (2).37 Therefore, ketone derivatives of the most effective esters were synthesized with the speculation that they should be more potent and more stable than their ester analogues. As expected, the ketone derivatives of CAPE (2) were generally as good or better inhibitors of 5-LO product biosynthesis as their ester analogues in both isolated PMNL and whole blood in short-term incubations. However, although the inhibitory capacity of all compounds appeared to be stable in plasma, only CAPE (2) and compound 7 rapidly lost their ability to inhibit leukotriene
biosynthesis following a preincubation in blood suggesting that the vicinal hydroxyl groups are susceptible to modification in whole blood.

Human HepaRG cells have been used in many studies as a valuable alternative to ex vivo cultivated primary human hepatocytes to evaluate drugs and perform drug metabolism studies. In such experiments HepaRG cells are differentiated into a hepatocyte-like morphology while conserving the expression of cytochrome P450 enzymes, transporter proteins, and transcription factors.43,44 The incubation of all test compounds with HepaRG cells resulted in the production of glucuronidated analogues, consistent with the known susceptibility of hydroxyl groups of phenolic compounds to sulfation and glucuronidation,56-58 although no sulfated analogues were detected. Interestingly, the half-life of the parent compounds in HepaRG cultures varied as the ketone derivatives all showed longer half-lives than the ester compounds, with the sinapic acid ketone compound 10 showing a significantly greater half-life than all other compounds. Although these in vitro results cannot predict with certainty which compounds will exhibit acceptable pharmacokinetic profiles, these results indicate that compound 10 is the preferred candidate for further in vivo evaluation. Moreover, compound 10 was the only molecule that retained inhibitory activity after 60 minutes in HepaRG culture despite the complete disappearance of the parent compound on HPLC chromatograms, suggesting that the glucuronide conjugate product exhibits inhibitory activity. These observations coupled with its near complete retention of inhibitory activity in whole blood after a 4-hour incubation and its excellent IC_{50} value further support the continued investigation of this compound for subsequent in vivo evaluation.

Another observation following LC-MS analysis of HepaRG cultures was the presence of [M-H]^{+} and [M + H_{2}H]^{+} ions in incubations that contained the ketone compounds but not the esters. The ions were resolved chromatographically and are likely the results α,β-unsaturated ketoalkene reductase that has been documented in the liver.59-61 Importantly, the saturated form of CAPE (2)29 was previously shown to be as effective for the inhibition of 5-LO product biosynthesis, thus the reduction of the α,β-unsaturated ketoalkene in the liver is unlikely to impact on the capacity of the ketone compounds to inhibit 5-LO product biosynthesis.

All tested compounds showed favorable physicochemical and ADME properties that are compatible with favorable pharmacokinetic and drug-likeness properties, as well as characteristics that are consistent with oral bioavailability. Indeed, all compounds adhered to Lipinski’s rule of 5 indicating that they do not trigger a computational alert for absorption or permeation that would suggest poor bioavailability.40 Compounds that trigger the alert are likely to be troublesome in subsequent in vivo studies. In a preliminary evaluation of the molecular interactions between selected compounds and 5-lipoxygenase, all compounds showed a stronger affinity to 5-LO than zileuton. Furthermore, several interactions were identified that are consistent with the inhibition of enzyme activity such as interactions with His 600 that may be necessary for the positioning of the arachidonic acid substrate (compounds 5 and 8), π-π interactions with Phe177 (compound 7) which may play role in product specificity39 and π-π interactions with His 372 (CAPE (2), 5, 9, 8 and 10) that suggest a good position to coordinate the iron atom or, at a minimum, block some access to the binding site cavity.

Although CAPE has been shown to be an excellent inhibitor of 5-LO product biosynthesis, a series of structure-activity relationship studies were undertaken to develop new compounds that possess enhanced biological activity.27,30,37 Predicting the best performing analogues has not been apparent. For example, the relation between the presence and position of dihydroxy groups or methoxy groups and inhibitory activity is critical but was not predictable. Similarly, different structural analogues of the ester moiety show significantly different inhibitory activity, and possessing radical scavenging activity comparable to that of CAPE does not translate into good 5-LO inhibition. Amongst the numerous CAPE analogues that have been evaluated, the 2,5-dihydroxy compounds (5 and 8) and the sinapic acid derivatives (9 and 10) described in this study are those that have shown the best inhibitory activity in isolated PMN and in whole blood. This study was the first to evaluate the biological stability of these analogues. While ketone derivatives showed better stability than esters, sinapic acid phenethyl ketone (10) showed the longest half-life and was the only molecule that maintained inhibitory activity in hepatocyte cultures. Overall, the excellent inhibition of 5-LO product biosynthesis in a complex matrix combined with its better stability and favorable physicochemical and ADME properties suggest that compound 10 is a good candidate for continued development in preclinical models of inflammatory diseases.

DISCLOSURE
Authors ME Surette and M Touaibia are the inventors of a patent application that describes some of the compounds reported in the current study.

AUTHOR CONTRIBUTIONS
Participated in research design: Surette, Mbarik and Poirier;
Performed data analysis: Surette, Mbarik, Doiron, Barnett, and Cormier;
Contributed new reagent or analytic tools: Selka, Touaibia;
Performed data analysis: Surette, Mbarik, Doiron, Barnett, and Touaibia;
Wrote or contributed to the writing of the manuscript: Mbarik, Touaibia, Barnett, and Surette.

FUNDING INFORMATION
This work was supported by grants from the National Sciences and Engineering Research Council of Canada; the New Brunswick Health Research Foundation; the New Brunswick Innovation Foundation.
REFERENCES

1. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science. 1983;220:568-575.

2. Borgeat P, Samuelsson B. Arachidonic acid metabolism in polymorphonuclear leukocytes: unstable intermediate in formation of dihydroxy acids. Proc Natl Acad Sci USA. 1979;76:3213-3217.

3. Borgeat P, Hamberg M, Samuelsson B. Transformation of arachidonic acid and homo-gamma-linolenic acid by rabbit polymorphonuclear leukocytes. Monohydroxy acids from novel lipoxigenases. J Biol Chem. 1976;251:7816-7820.

4. Borgeat P, Samuelsson B. Transformation of arachidonic acid by rabbit polymorphonuclear leukocytes. Formation of a novel dihydroxyeicosatetraenoic acid. J Biol Chem. 1979;254:2643-2646.

5. Murphy RC, Gijón MA. Biosynthesis and metabolism of leukotrienes. Biochem J. 2007;405:379-395.

6. Murphy RC, Hammarsström S, Samuelsson B. Leukotriene C: a slow-reacting substance from murine mastocytoma cells. Proc Natl Acad Sci USA. 1979;76:4275-4279.

7. Peters-Golden M, Henderson WR. Leukotrienes. N Engl J Med. 2007;357:1841-1854.

8. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-867.

9. Kalinkovich A, Gabdulina G, Livshits G. Autoimmunity, inflammation, and dysbiosis mutually govern the transition from the preclinical to the clinical stage of rheumatoid arthritis. ImmunoL Res. 2018;66:696-709.

10. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32:2045-2051.

11. Murdoch JR, Lloyd CM. Chronic inflammation and asthma. Mutat Res. 2010;690:24-39.

12. Chen M, Lam BK, Kanaoka Y, et al. Neutrophil-derived leukotriene B4 is required for inflammatory arthritis. J Exp Med. 2006;203:837-842.

13. Left JA, Busse WW, Pearlman D, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med. 1998;339:147-152.

14. Mehrabian M, Alayee H, Wong J, et al. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res. 2002;91:120-126.

15. Wejksza K, Lee-Chang C, Bodogai M, et al. Cancer-produced metabolites of 5-lipoxygenase induce tumor-evoked regulatory B cells via peroxisome proliferator-activated receptor α. J Immunol. 2013;190:2575-2584.

16. Haeggström JZ. Leukotriene biosynthetic enzymes as therapeutic targets. J Clin Invest. 2018;128:2680-2690.

17. Wenzel SE, Kamada AK. Zileuton: the first 5-lipoxygenase inhibitor for the treatment of asthma. Ann Pharmacother. 1996;30:858-864.

18. Berger W, Chandt M, Cairns CB. Zileuton: clinical implications of 5-lipoxygenase inhibition in severe airway disease. Int J Clin Prac. 2007;61:663-676.

19. Israel E, Cohn J, Dubé L, Drazen JM. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. JAMA. 1996;275:931-936.

20. Joshi EM, Heasley BH, Macdonald TL. 2-ABT-S-oxide detoxification by glutathione S-transferases A1-1, M1-1 and P1-1: implications for toxicity associated with zileuton. Xenobiotica Fate Foreign Compd Biol Syst. 2009;39:197-204.

21. Steinhilber D, Hofmann B. Recent advances in the search for novel 5-lipoxygenase inhibitors. Basic Clin Pharmacol Toxicol. 2011;104:70-77.

22. Grunberger D, Banerjee R, Eisinger K, et al. Preferential cytotoxicity on tumor cells by caffeic acid phenethyl ester isolated from propolis. Experientia. 1988;44:230-232.

23. Akyol S, Isik B, Altuntas A, et al. Future opportunities in preventing ototoxicity: caffeic acid phenethyl ester may be a candidate (Review). Mol Med Rep. 2015;12:3231-3235.

24. Erdemli HK, Akyol S, Armutcu F, Akyol O. Antibiral properties of caffeic acid phenethyl ester and its potential application. J Intercult Ethnopharmacol. 2015;4:344-347.

25. Sun L, Liao K, Hang C. Caffeic acid phenethyl ester synergistically enhances the antifungal activity of fluconazole against resistant Candida albicans. Phytomedicine Int J Phytother Phytopharm. 2018;40:55-58.

26. Zabaiou N, Fouache A, Trousson A, et al. Biological properties of propolis extracts: something new from an ancient product. Chem Phys Lipids. 2017;207:214-222.

27. Boudreau LH, Maillet J, LeBlanc LM, et al. Caffeic acid phenethyl ester and its amide analogue are potent inhibitors of leukotriene biosynthesis in human polymorphonuclear leukocytes. PLoS ONE. 2012;7:e31833.

28. Boudreau LH, Lassalle-Claus G, Cormier M, et al. New hydroxycinnamic acid esters as novel 5-lipoxygenase inhibitors that affect leukotriene biosynthesis. Mediators Inflamm. 2017:2017:e0132607.

29. Touabia M, Hébert M, Levesque NA, et al. Sinapic acid phenethyl ester enhances the antifungal activity of fluconazole against C. albicans. J Basic Clin Pharmacol Toxicol. 2014;114:70-77.

30. Selka A, Doiron JA, Lyons P, et al. Discovery of a novel 2,5-dihydroxycinnamic acid-based 5-lipoxygenase inhibitor that induces apoptosis and may impair autophagic flux in RCC4 renal cancer cells. Eur J Med Chem. 2019;179:347-357.

31. Alain EP, Boudreau LH, Flamand N, Surette ME. The intracellular localisation and phosphorylation profile of the human 5-lipoxygenase. Biochem J. 2015;464:323-3235.

32. Robichaud PP, Poirier SJ, Boudreau LH, et al. On the cellular mechanisms of caffeic acid phenethyl ester and its amide analogue. J Intercult Ethnopharmacol. 2016;2016:e0132607.

33. Boudreau LH, Poirier SJ, Boudreau LH, et al. On the cellular mechanisms of caffeic acid phenethyl ester and its amide analogue. J Intercult Ethnopharmacol. 2016;690:24-39.

34. Surette ME, Odeimat A, Palmantier R, Marleau S, Poubelle PE, Borgeat P. Reverse-phase high-performance liquid chromatography analysis of arachidonic acid metabolites in plasma after stimulation of whole blood ex vivo. Anal Biochem. 1994;216:392-400.
35. Gilbert NC, Bartlett SG, Waht MT, et al. The structure of human 5-lipoxygenase. *Science*. 2011;331:217-219.
36. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. *J Comput Chem*. 2010;31:455-461.
37. Doiron JA, Leblanc LM, Hébert M, et al. Structure-activity relationship of caffeic acid phenethyl ester analogs as new 5-lipoxygenase inhibitors. *Chem Biol Drug Des*. 2017;89:514-528.
38. Rådmark O, Werz O, Steinbülb D, Samuelsson B. 5-Lipoxygenase, a key enzyme for leukotriene biosynthesis in health and disease. *Biochim Biophys Acta - Mol Cell Biol Lipids*. 2015;1851:331-339.
39. Mitra S, Bartlett SG, Newcomer ME. Identification of the substrate access portal of 5-Lipoxygenase. *Biochemistry*. 2015;54:6333-6342.
40. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv Drug Deliv Rev*. 2001;46:3-26.
41. Veber DF, Johnson SR, Cheng H-Y, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. *J Med Chem*. 2002;45:2615-2623.
42. Meanwell NA. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. *Chem Res Toxicol*. 2011;24:1420-1456.
43. Kanebratt KP, Andersson TB. Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. *Drug Metab Dispos*. 2008;36:1444-1452.
44. Marion M-J, Hantz O, Durantel D. The HepaRG cell line: biological properties and relevance as a tool for cell biology, drug metabolism, and virology studies. *Methods Mol Biol*. 2010;640:261-272.
45. Chen M, Lam BK, Luster AD, et al. Joint tissues amplify inflammation and alter their invasive behavior via leukotriene B4 in experimental inflammatory arthritis. *J Immunol*. 2010;185:5503-5511.
46. Miyabe Y, Miyabe C, Luster AD. LTB4 and BTL1 in inflammatory arthritis. *Semin Immunol*. 2017;33:52-57.
47. Bertrand M-J, Tardif J-C. Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis. *Expert Opin Emerg Drugs*. 2017;22:1-26.
48. Hoxha M, Rovati GE, Cavanillas AB. The leukotriene receptor antagonist montelukast and its possible role in the cardiovascular field. *Eur J Clin Pharmacol*. 2017;73:799-809.
49. Hoxha M, Lewis-Mikhael A-M, Bueno-Cavanillas A. Potential role of leukotriene receptor antagonists in reducing cardiovascular and cerebrovascular risk: a systematic review of human clinical trials and in vivo animal studies. *Biomed Pharmacother Biomedicine Pharmacother*. 2018;106:956-965.
50. Giannopoulos PF, Chiu J, Praticò D. Anti-leukotriene therapy by reducing tau phosphorylation improves synaptic integrity and cognition of P301S transgenic mice. *Aging Cell*. 2018;17:e12759.
51. Chen Y, Hu Y, Zhang H, Peng C, Li S. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. *Nat Genet*. 2009;41:783-792.
52. Hu Y, Li S. Survival regulation of leukemia stem cells. *Cell Mol Life Sci*. 2016;73:1039-1050.
53. Celli N, Dragni LK, Murzilli S, Pagliani T, Poggi A. In vitro and in vivo stability of caffeic acid phenethyl ester, a bioactive compound of propolis. *J Agric Food Chem*. 2007;55:3398-3407.
54. Celli N, Mariani B, Dragni LK, Murzilli S, Rossi C, Rotilio D. Development and validation of a liquid chromatographic-tandem mass spectrometric method for the determination of caffeic acid phenethyl ester in rat plasma and urine. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2004;810:129-136.
55. Wang X, Pang J, Maffucci JA, et al. Pharmacokinetics of caffeic acid phenethyl ester and its catechol-ring fluorinated derivative following intravenous administration to rats. *Biopharm Drug Dispos*. 2009;30:221-228.
56. Gao S, Hu M. Bioavailability challenges associated with development of anti-cancer phenolics. *Mini Rev Med Chem*. 2010;10:550-567.
57. Wu B, Kulkarni K, Basu S, Zhang S, Hu M. First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics. *J Pharm Sci*. 2011;100:3655-3681.
58. Wu B, Basu S, Meng S, Wang X, Zhang S, Hu M. Regioselective sulfation and glucuronidation of phenolics: insights into the structural basis of conjugation. *Curr Drug Metab*. 2011;12:900-916.
59. Kitamura S, Tatsumi K. Purification of NADPH-linked alpha,beta-alkene double bond reductase from rat liver. *Arch Biochem Biophys*. 1990;282:183-187.
60. Lindstrom TD, Whitaker GW. Saturation of an alpha, beta-unsaturated ketone: a novel xenobiotic biotransformation in mammals. *Xenobiotica*. 1984;14:503-508.
61. Yu L, Jiang Y, Wang L, Sheng R, Hu Y, Zeng S. Metabolism of BYZX in human liver microsomes and cytosol: identification of the metabolites and metabolic pathways of BYZX. *PLoS ONE*. 2013;8:e59882.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Mbarik M, Poirier SJ, Doiron J, et al. Phenolic acid phenethylesters and their corresponding ketones: Inhibition of 5-lipoxygenase and stability in human blood and HepaRG cells. *Pharmacol Res Perspect*. 2019;e00524. [https://doi.org/10.1002/prp2.524](https://doi.org/10.1002/prp2.524)